Wattanachayakul Phuuwadith, Kittipibul Veraprapas, Fudim Marat
Department of Medicine, Jefferson Einstein Hospital, Philadelphia, PA, USA.
Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA.
Heart Fail Rev. 2025 Sep;30(5):1093-1097. doi: 10.1007/s10741-025-10511-4. Epub 2025 Apr 9.
ZOLL Heart Failure Management System (ZOLL HFMS) is a non-invasive, remote monitoring device that employs radiofrequency signals transmitted through an adhesive patch embedded with integrated sensors to evaluate lung fluid levels. By analyzing trends in lung fluid status and related parameters, ZOLL HFMS may facilitate the early detection of heart failure (HF) decompensation and enable timely interventions. Insights from the recent BMAD trial (Impact of heart failure management using thoracic fluid monitoring from a novel wearable sensor: Results of the Benefits of Microcor [µCor™] in Ambulatory Heart Failure) highlight its promise in those with recent HF hospitalization, demonstrating a reduction in time to first HF readmission and improvement in quality of life. In this review, we summarize data on the ZOLL HFMS, with a focus on its lung fluid analysis mechanism for early HF decompensation detection and the accuracy of its measurements compared to other modalities. Then, we examine key outcomes from the recent BMAD trial, highlighting their clinical relevance and identifying gaps that warrant further investigation in future clinical trials. Lastly, we outline potential directions for integrating this technology into routine HF management.
ZOLL心力衰竭管理系统(ZOLL HFMS)是一种非侵入性远程监测设备,它利用通过嵌入集成传感器的粘性贴片传输的射频信号来评估肺液水平。通过分析肺液状态和相关参数的趋势,ZOLL HFMS可有助于早期发现心力衰竭(HF)失代偿并实现及时干预。近期BMAD试验(使用新型可穿戴传感器进行胸液监测对心力衰竭管理的影响:微芯[µCor™]在门诊心力衰竭中的益处结果)的见解突出了其在近期有HF住院患者中的前景,显示首次HF再入院时间缩短且生活质量得到改善。在本综述中,我们总结了关于ZOLL HFMS的数据,重点关注其用于早期HF失代偿检测的肺液分析机制以及与其他方式相比其测量的准确性。然后,我们研究近期BMAD试验的关键结果,突出其临床相关性并确定在未来临床试验中需要进一步研究的差距。最后,我们概述了将该技术整合到常规HF管理中的潜在方向。